Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction (MARBLE): A Phase 2 Trial to Evaluate the Efficacy and Feasibility of the Apolipoprotein E Mimetic Peptide, CN-105, in Preventing Postoperative Cognitive Dysfunction and Delirium and Blocking Their Underlying Neural Mechanisms
Latest Information Update: 21 Oct 2024
At a glance
- Drugs CN 105 (Primary)
- Indications Cognition disorders; Delirium; Postoperative complications
- Focus Adverse reactions
- Acronyms MARBLE
Most Recent Events
- 22 Feb 2023 Status changed from recruiting to completed.
- 23 Aug 2022 Planned End Date changed from 17 Dec 2023 to 1 Mar 2023.
- 23 Aug 2022 Planned primary completion date changed from 17 Dec 2022 to 1 Mar 2023.